Press Release

<< Back
View printer-friendly version

Spark Therapeutics to Host Conference Call on Wednesday, Aug. 2 at 8:30 a.m. ET to Discuss Second Quarter 2017 Results

PHILADELPHIA, July 28, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Wednesday, Aug. 2, 2017 at 8:30 a.m. ET to discuss financial results for the second quarter that ended June 30, 2017 and recent business highlights.

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 62580535. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 62580535, or by visiting the “Investors” section at www.sparktx.com.

About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform has successfully delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, with proposed trade name LUXTURNA™ (voretigene neparvovec), is currently under Priority Review with FDA for the treatment of biallelic RPE65-mediated IRD and has been designated as a drug for a rare pediatric disease. It previously received breakthrough therapy and orphan product designations from FDA and orphan product designations from the European Medicines Agency (EMA). The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001(which also has received both breakthrough therapy and orphan product designations by FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. For more information, visit www.sparktx.com.

Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424

Media Contact:
Monique da SilvaMonique.dasilva@sparktx.com
215-282-7470

Primary Logo

Spark Therapeutics, Inc.